We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Avacta Group Plc | AVCT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.25 | -0.53% | 46.50 | 15:06:30 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 45.75 | 45.25 | 46.50 | 46.50 | 46.75 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 29/4/2024 15:45 by amanitaangelicus Whitey ... what are you burbling on about? MTD ... every drug has side effects ...peeps will react differently too. Remember the covid vacc warnings ...% of various known side effects pointed out. AVA6k will ,eventually, have a similar risk profile, but work needs doing here. Need efficacy dose sorting now. Please stop being childish, we are serious investors here, unlike you. No Green Eyed Monster responses - look at the share price All about set up plays. Told ya countless times. You can do it. Attachild. |
Posted at 27/4/2024 15:22 by pwhite73 Down here nobody cares about conviboys, MM games, longs or shorts. This is why the thread is so quiet despite an 8% rise yesterday.What investors want to see is evidence the drug actually works. People who don't know or think they know what's going on blame the falling share price on the death spiral. I've said it before and I'll say it again AVCT does not have death spiral financing and even if it did it is not the reason why the share price has dropped from 180p in February last year to 48p today. The problem for AVCT is that the commercial pharmacology industry has seen no evidence to date that suggests AVA6000 is an improvement on Dox on its own. The data presented so far is not independent and there is no peer review in any medical journals to confirm even partial efficacy of AVA6000. As result of this AVCT cannot source the $billions of dollars normally available for early stage cancer drugs that show promising potential. This is why it had to tap the AIM mug punter market at 50p and not 500p. I have opined countless times before and will say so again AVA6000 is as bogus as the world beating LFT and it does please me that many of my earlier and later critics are beginning to see that I was right all along. |
Posted at 22/4/2024 16:54 by jaknife PWhite73,"Jaknife - "You need to use the 10% discount to VWAP part of the formula" Come on spit it out. What is the VWAP price they are using over how many days and which days?" I posted the formula in 57,557: ==================== Share Payments: For any interest and amortisation payments made in Ordinary Shares (which shall be subject to certain conditions including no potential event of default having occurred and maintenance of a minimum free float), the Ordinary Shares to be delivered shall be calculated by dividing the interest or amortisation amount due by the lower of (a) the prevailing conversion price, in each case on the applicable repayment date and (b) 90 per cent. of the Market Price per Ordinary Share (as defined below) The "Market Price" is the lower of the arithmetic average of the VWAP for the Ordinary Shares: (i) on the ten (10) trading days, ending on the applicable date or (ii) on the five (5) trading days, ending on the applicable date, but in no event shall it be greater than the VWAP of the Ordinary Shares on the applicable date ==================== "RNS 18/10/2022 - "Convertible Bond Investor agrees not to sell Ordinary Shares (or any interest in them) nor engage in any short sale transactions in Ordinary Shares (or any interest in them) of the Company during any relevant calculation period, subject to certain exceptions" As I noted above, the Investor is a subsidiary of a large market maker (Susquehanna). The restrictions that you've posted above apply to "Investor", however, they don't apply to the market maker, which is a separate legal entity. "No it is not and it's important to understand the difference between the two. Nobody was screaming death spiral finance when this hit 180p in February last year." We don't agree on this point but you will find that I was noting that this was a death spiral convertible right from day one, when it was first issued and presented in a manner that made people think that it was a genuine convertible rather than a death spiral convertible. It's amusing but the investor into this death spiral is the same as the investor into the Pantheon Resources death spiral. The PANR shareholders also insisted for many months that it wasn't a death spiral, however, now they accept that it is! JakNife |
Posted at 22/4/2024 15:05 by pwhite73 Jaknife - "You need to use the 10% discount to VWAP part of the formula"Come on spit it out. What is the VWAP price they are using over how many days and which days? Jaknife - "Better than that, the investor into the loan note is a subsidiary of a large market maker (Susquehanna) and market makers are legally permitted to naked short (and are also exempt from the short selling disclosure rules). Hence, between them, the investor and Susquehanna can forward sell the shares!" RNS 18/10/2022 - "Convertible Bond Investor agrees not to sell Ordinary Shares (or any interest in them) nor engage in any short sale transactions in Ordinary Shares (or any interest in them) of the Company during any relevant calculation period, subject to certain exceptions" |
Posted at 22/4/2024 14:44 by jaknife stockhunters,"why issue shares at 42p when they turned down even more money in the 50p placing?" Avacta issued a £55m convertible loan note 18 months ago: The quarterly repayments under the loan can either be paid in cash or shares. If the company elects to repay with shares then there's a formula to determine the number of shares that are issued: ==================== Share Payments: For any interest and amortisation payments made in Ordinary Shares (which shall be subject to certain conditions including no potential event of default having occurred and maintenance of a minimum free float), the Ordinary Shares to be delivered shall be calculated by dividing the interest or amortisation amount due by the lower of (a) the prevailing conversion price, in each case on the applicable repayment date and (b) 90 per cent. of the Market Price per Ordinary Share (as defined below) The "Market Price" is the lower of the arithmetic average of the VWAP for the Ordinary Shares: (i) on the ten (10) trading days, ending on the applicable date or (ii) on the five (5) trading days, ending on the applicable date, but in no event shall it be greater than the VWAP of the Ordinary Shares on the applicable date ==================== "also can they sell the 42p shares instantly or are they locked in?" Better than that, the investor into the loan note is a subsidiary of a large market maker (Susquehanna) and market makers are legally permitted to naked short (and are also exempt from the short selling disclosure rules). Hence, between them, the investor and Susquehanna can forward sell the shares! PWhite73, "I'm also puzzled as to where they've got the 42p from. RNS 22/04/24 - "The 15-Day Reset Average Market Price is 50.83 pence" 42p is a drop of 17.5% on 50.83p" You're using the wrong part of the formula. See above. You need to use the 10% discount to VWAP part of the formula, as I noted in posts 57,542 and 57,549. JakNife |
Posted at 11/4/2024 15:26 by jaknife jacktrax,"Taking part in that placing Jak , the one for existing shareholders , so you held shares Jak , give me the clever words and shoot me down but I think you are telling porkies" The placing was open to any professional investor. You didn't need to be a shareholder to participate. If you read the original placing RBS, for example, you will find the words: "The Placing will be conducted through an accelerated bookbuild (the "Bookbuild") which will be launched immediately following this announcement (being, together with the Appendices hereto, this "Announcement") and will be made available to new and existing institutional investors." [my bold] see: JakNife |
Posted at 26/3/2024 18:47 by ohwhatfun Avacta stuck out like a sore thumb, flying high in a market where promising ideas have been destroyed. Many diluted into oblivion or now bust.The Avacta crazy market cap was down to a long run of excessive pumping by Myles and co, to a retail army oblivious to/stubborn ignorance of the risks. A fund raise was nailed on and at significant discount, a plethora of small caps have followed the same fate. It was blatantly obvious what was coming but due the fantasy forecasts in notes by the pumpers along with a social media frenzy, ably assisted by the CEO, private investors got mugged. The blame lies entirely with the fantasy crew, completely ignoring the obvious, including positive posts, dragging in buyers, just before the guillotine fell. Investors thought the pumpers had inside information, raise not coming, ignore the warnings. This remains very high risk, and will do for quite some time. The pumping frenzy simply offered an opportunity for some to go short, who anticipated, with good reason, that a heavily discounted raise would come. It did, they were right, believed favoured pump crew, wrong. That’s about it, stop trying to deflect the reality, the CEO and pump crew sucked in buyers, and stiffed them good and proper. |
Posted at 02/3/2024 09:46 by rajraj b Also, thank you for clarifying that the new institutional investors are AJ Bell, Interactive Investor and Hargreaves Lansdowne in the capacity as holding accts. Seems strange that AS would want to fool/mislead people that way. That's very deceitful if that's the case. Or maybe there could be some real II involved? Can't remember what the minimum holding is required before a TR1 is needed. |
Posted at 21/2/2024 10:13 by ohwhatfun LogSome points. Avacta is far too early in process (trials) to attract backers, the numbers involved are too low. Hence that is a very slim chance event. Even then it appears increased doses failed to meet the same standard as the original Dox, safety up efficacy not. Not an efficacy trial they say, safety, but it's sample of efficacy regardless of the phase 1 label. There are a host of phase 1 safety trials where efficacy has been better than the standard of care. April, Bond. I'm trying to get my head around the bond, your April comment, floor reset 18 months, the lower limit appears to be 95p But then it states "save in limited circumstances there is a reset price floor of 95p" No explanation of that, but I guess the limited circumstances relate to share price performance (EG 95p breached), so that floor of 95p is likely to drop, potentially materially. The bond can also convert partially at any time at the bond holders discretion. As is typical, the full details about the bond are not in there. Always fun to see negativity thrown at warning posts about how vicious the city can be when it comes to fund raise time. Pure tunnel vision by the city vultures, crash it as much as possible to maximise returns, they don't give a damn about the company. Private investors seem to fight against what is blatantly obvious, a hope that some Good Samaritan will appear with the cash, ignoring the likely discounted fund raise reality. Fingers crossed there are not too many private investors geared beyond their means, there are always some, and no doubt sleepless nights already in play. I do not wish those crash events on them, it's vile, they get wiped out, the city does not care, it's just another successful day at the office to them, |
Posted at 19/2/2024 09:28 by loglorry1 I have no clue if their story holds up and unless you have a PhD and a lot of experience in the exact field nor do you. I very much doubt anyone on this board has the expertise to evaluate their claims and probably none of the private investors that hold the shares does either. Even if they did they wouldn't have access to the data required to evaluate their claims.There are no peer reviewed independently funded papers of their claims either which is a red flag for me. The company engages in a massive amount of financial PR targeted at private investors another red flag. Saying all that if enough people believe and buy the shares the share price will go up. From what I know of your posts on CINE PWhite, your analysis of these situations isn't much good either. Do you have the experience and relevant data to provide input on the science? From what I can tell of @tickboo is that he buys story stocks. I don't think he has any track record of success but like everyone he might have got a bit lucky here and there. He probably sold a lot of his holding much higher but he'll never admit it. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
